Management of advanced epithelial ovarian cancer in the older patient: an age stratified cohort study of a gynaecological cancer centre in Southern England

This was an age-stratified, retrospective, cohort study of patients between the ages of 65–69, 70–75 and ≥76 years diagnosed with high grade serous ovarian cancer of FIGO (2014) Stage 3a or higher between 01 January 2017 and April 2020. The study aimed to examine and compare patient characteristics, treatments and outcomes, including survival, of elderly patients within a single cancer centre in the south of England. Data collection began in January 2021 and concluded in March 2022. Ninety patients were eligible for the study. A correlation was observed between increasing age and worsening performance status (p = 0.044). Other variables assessed included age at diagnosis and time between decision to treatment, however, there was no evidence of correlations. The majority of patients studied received neoadjuvant chemotherapy followed by cytoreductive surgery as their primary treatment modality, however, 53%of our eldest cohort underwent treatment types that did not involve surgery. Of those who did undergo surgery, there was no observed correlation between age and the rates of complete cyto-reductive surgery, intra-operative complications, admission to High Dependency Unit, or length of hospital stay. Median length of stay across all age groups was 5 days. Patients ≥76 years were more likely to receive single-agent carboplatin (p = 0.009) than dual-agent chemotherapy. There was no increase in chemo-toxicity events with increasing age. While primary cytoreductive surgery is favoured by many gynaecological oncology teams, neoadjuvant chemotherapy still offers a viable treatment alternative for elderly and frail patients with advanced stage ovarian cancer by minimising operative times, reducing admissions to high dependency units and shortening lengths of hospital stay. Geriatric assessments, in combination with performance status, may aid treatment decisions made by the multi-disciplinary team.

Care of the older patient; Ovarian cancer; Cancer surgery; Operative time; Chemotherapy

[1] Office for National Statistics. Cancer registration statistics. 2017. Available at: www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland/2016/2016cancerregistrationsreferencetablesfinal.xls (Accessed: 21 April 2024).

[2] National Ovarian Cancer Audit Feasibility Pilot (NOCAFP). Disease profile in England: incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas. 2020. Available at: https://digital.nhs.uk/ndrs/data/data-outputs/ovarian-cancer-audit-feasibility-pilot-ocafp---project-summary-report/disease-profile-in-england (Accessed: 25 May 2024).

[3] Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017; 213: 123–139.

[4] Cancer Research UK. Ovarian cancer survival. 2023. Available at: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/survival (Accessed: 21 April 2024).

[5] Dumas L, Bowen R, Butler J, Banerjee S. Under-treatment of older patients with newly diagnosed epithelial ovarian cancer remains an issue. Cancers. 2021; 13: 952.

[6] Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. Journal of Clinical Oncology. 2011; 29: 3921–3926.

[7] Joueidi Y, Dion L, Bendifallah S, Mimoun C, Bricou A, Nyangoh Timoh K, et al. Management and survival of elderly and very elderly patients with ovarian cancer: an age-stratified study of 1123 women from the FRANCOGYN group. Journal of Clinical Medicine. 2020; 9: 1451.

[8] Liontos M, Papatheodoridi A, Andrikopoulou A, Thomakos N, Haidopoulos D, Rodolakis A, et al. Management of the elderly patients with high-grade serous ovarian cancer in the REAL-WORLD setting. Current Oncology. 2021; 28: 1143–1152.

[9] Jørgensen TL, Teiblum S, Paludan M, Poulsen LØ, Jørgensen AYS, Bruun KH, et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecologic Oncology. 2012; 127: 367–374.

[10] Langstraat C, Cliby WA. Considerations in the surgical management of ovarian cancer in the elderly. Current Treatment Options in Oncology. 2013; 14: 12–21.

[11] Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, et al. Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. Aging and Disease. 2017; 8: 677.

[12] Janda M, Youlden DR, Baade PD, Jackson D, Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? International Journal of Gynecologic Cancer. 2008; 18: 896–907.

[13] World Health Organisation. International statistical classification of diseases and related health problems 10th revision. 2023. Available at: https://icd.who.int/browse10/2019/en#/C56 (Accessed: 21 April 2024).

[14] Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology & Obstetrics. 2014; 124: 1–5.

[15] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987; 40: 373–383.

[16] Aletti G, Santillan A, Eisenhauer E, Hu J, Aletti G, Podratz K, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecologic Oncology. 2007; 107: 99–106.

[17] Hawarden A, Russell B, Gee ME, Kayali F, Clamp A, Crosbie EJ, et al. Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study. BMC Cancer. 2021; 21: 378.

[18] Schuurman MS, Kruitwagen RFPM, Portielje JEA, Roes EM, Lemmens VEPP, van der Aa MA. Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis. Gynecologic Oncology. 2018; 149: 270–274.

[19] Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine. 2010; 363: 943–953.

[20] Ceccaroni M, D’Agostino G, Ferrandina G, Gadducci A, Di Vagno G, Pignata S, et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecologic Oncology. 2002; 85: 445–450.

[21] Falandry C, Savoye AM, Stefani L, Tinquaut F, Lorusso D, Herrstedt J, et al. EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study. Journal of Clinical Oncology. 2019; 37: 5508–5508.

[22] Kim J, Hurria A. Determining chemotherapy tolerance in older patients with cancer. Journal of the National Comprehensive Cancer Network. 2013; 11: 1494–1502.

[23] Nordin A, Sundar S, Nieto J, Eversfield C, Turner C, Knott C, et al. Ovarian cancer audit feasibility pilot, short-term mortality in ovarian, fallopian tube and primary peritoneal carcinomas across England. 2022. Available at: https://digital.nhs.uk/ndrs/data/data-outputs/ovarian-cancer-audit-feasibility-pilot-ocafp---project-summary-report/short-term-mortality-across-england (Accessed: 25 May 2024).

[24] Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, et al. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstetrics & Gynecology. 2015; 125: 1345–1352.

[25] Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology. 2011; 123: 187–191.

[26] Sbai M, Jasper E, Martin F, Rajkumar S, Montes A, Jeyarajah J, et al. Shared decision making in gynaecological oncology; a challenge in an ageing population. The Obstetrician & Gynaecologist. 2021; 23: 290–294.

[27] Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. The Lancet. 2013; 381: 752–762.

[28] Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2001; 56: M146–M157.

[29] Verweij NM, Schiphorst AHW, Pronk A, van den Bos F, Hamaker ME. Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncologica. 2016; 55: 1386–1391.

[30] Cesari M, Cerullo F, Zamboni V, Di Palma R, Scambia G, Balducci L, et al. Functional status and mortality in older women with gynecological cancer. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2013; 68: 1129–1133.

[31] Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. Journal of Clinical Oncology. 2018; 36: 2326–2347.

[32] Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. The Lancet. 2021; 398: 1894–1904.